Lin Lin, MD, highlights a phase 2 trial of neoadjuvant SAbR followed by surgery in patients with newly diagnosed renal cell carcinoma and caval tumor thrombus. DFS rate was 85.3% at 6 months (95% CI, ...

The combination demonstrated a disease-specific survival rate of 98.7% at 12 months and 96.0% at 36 months. This episode offers practical insights for clinicians navigating complex prostate cancer ...

The group agreed that the future of NMIBC treatment depends on biomarkers that can direct patients toward the therapy most likely to work. The group agreed that treatment selection for ...

Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

DARE to PLAY is a topical sildenafil cream enhancing female arousal, available in select states as a compounded product while awaiting FDA approval. Clinical trials showed improved arousal sensation ...

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today. "I think MRI has really been perhaps the most transformative development in the realm of ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

Bladder Cancer | Clinical | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

"We are not offering patients comprehensive management unless we consider hormone therapies," says Ashley G. Winter, MD. On July 17, 2025, a panel of experts convened by the FDA outlined the growing ...

NCCN guideline-recommended treatments significantly reduce prostate cancer mortality compared to other causes, even in high-risk patients. The study involved 135,636 Swedish patients, with 46% ...

Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...